The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Long-term follow-up of psilocybin-facilitated smoking cessation
Open accessAbstract
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. METHODS: The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. RESULTS: All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. CONCLUSION: These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously noted, mindfulness practices facilitate behavioral change by enabling individuals to identify triggers and habitual responses, whereas psychedelic therapy can amplify this awareness, resulting in even deeper behavioral transformations [33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Classic psychedelics, such as synthetic LSD and psilocybin, which is found in certain mushrooms, have shown promise as aids in psychotherapy e.g., for mood disorders and substance dependence [1, 5, 33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is emerging evidence from early phase trials of nicotine dependence (14)”
From Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Psilocybin-assisted psychotherapy (PAT) also appears to be safe and potentially efficacious for substance use disorders, based on early trials for nicotine and alcohol use disorders [14,15], with little evidence of harmful use in the community [16].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“Psilocybin occasioned mystical experiences are defined by acute feelings of unity, sacredness, a noetic quality, positive mood, transcendence of space/time, and ineffability (6), and have previously shown a significant association with successful psilocybinfacilitated smoking cessation outcomes at 6-month followup (11…”
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“psilocybin-facilitated treatment of alcohol dependence (24), the present findings indicate that 5-HT2AR agonists may hold therapeutic potential in treating a variety of”
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 4×
“Consistent with previously published data (4), no participants reported an increase in bothersome visual”
InfluentialSelf-citationGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Self-citationValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Self-citationLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Self-citation
Research works printed but not linked: 1
- World Health Organization, 2011, WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco
Cited by
Sorted by citations
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Self-citationPsychedelics, meditation, and self-consciousness
Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01475 · Cited by 390
Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375
Self-citationPsychedelics as Medicines: An Emerging New Paradigm
Nichols, D. E., Johnson, M., & Nichols, C. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.557 · Cited by 397
Self-citationJohnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
Self-citationAndersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J. S., Salam, I., Neill, J. C., & Nutt, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 359
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
Psychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306
The neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 330
Potential Therapeutic Effects of Psilocybin
Johnson, M. W., & Griffiths, R. R. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0542-y · Cited by 328
Self-citationPsychedelic therapy for smoking cessation: qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780612 · Cited by 285
Self-citationCessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Self-citationHalberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278
The hidden therapist: evidence for a central role of music in psychedelic therapy
Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmermann, C., Rodriguez, N., Roseman, L., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4820-5 · Cited by 303
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
Mason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0718-8 · Cited by 258
Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 279
Brain States and Transitions: Insights from Computational Neuroscience
Kringelbach, M. L., & Deco, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108128 · Cited by 249
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 270
Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788155 · Cited by 250
The Therapeutic Potential of Psilocybin
Lowe, H. I. C., Toyang, N. J., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W. F., & Gordon, L. (2021) · Molecules · doi:10.3390/molecules26102948 · Cited by 282
Long-lasting subjective effects of LSD in normal subjects.
Schmid, Y., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4733-3 · Cited by 232
Hartogsohn, I. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00129 · Cited by 229
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis
Goldberg, S. B., Pace, B. T., Nicholas, C. R. N., Raison, C. L., & Hutson, P. R. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112749 · Cited by 231
Developing Guidelines and Competencies for the Training of Psychedelic Therapists
Phelps, J. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817711304 · Cited by 225
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
Mertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119895520 · Cited by 208
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Wolff, M., Evens, R., Mertens, L. J., Koslowski, M., Betzler, F., Gründer, G., & Jungaberle, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00005 · Cited by 205
Must Psilocybin Always “Assist Psychotherapy”?
Goodwin, G. M., Malievskaia, E., Fonzo, G. A., & Nemeroff, C. B. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20221043 · Cited by 195
Garcia‐Romeu, A., & Richards, W. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1486289 · Cited by 210
Self-citationAwe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy
Hendricks, P. S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1474185 · Cited by 188
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171
Ketamine for the treatment of addiction: evidence and potential mechanisms
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.017 · Cited by 163
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
Peck, S. K., Shao, S., Gruen, T., Yang, K. H., Babakanian, A., Trim, J., Finn, D. M., & Kaye, W. H. (2023) · Nature Medicine · doi:10.1038/s41591-023-02455-9 · Cited by 171
Garcia‐Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00955 · Cited by 171
Self-citationPsychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155
Gukasyan, N., & Nayak, S. M. (2021) · Transcultural Psychiatry · doi:10.1177/1363461520983684 · Cited by 159
Chapter 33. Neuroscience of Psychotherapy
Vaughan, S., & Ahmed, M. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg33 · Cited by 152
Yao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 162
Ethics and ego dissolution: the case of psilocybin
Smith, W. R., & Sisti, D. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2020-106070 · Cited by 146
Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1580804 · Cited by 172
Ethical and legal issues in psychedelic harm reduction and integration therapy
Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J., & Narloch, V. F. (2021) · Harm Reduction Journal · doi:10.1186/s12954-021-00489-1 · Cited by 141
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Lindsey, H. M., Pittman, B. P., Cozzi, N. V., & D’Souza, D. C. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00962-y · Cited by 147
Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
Therapeutic effect of psilocybin in addiction: A systematic review
van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1134454 · Cited by 127
Milne, N., Thomsen, P. T., Knudsen, N., Rubaszka, P., Kristensen, M., & Borodina, I. (2020) · Metabolic Engineering · doi:10.1016/j.ymben.2019.12.007 · Cited by 125
Psychedelic microdosing benefits and challenges: an empirical codebook
Anderson, T., Petranker, R., Christopher, A., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2019) · Harm Reduction Journal · doi:10.1186/s12954-019-0308-4 · Cited by 133
Microdosing psychedelics: Motivations, subjective effects and harm reduction
Lea, T., Amada, N. M., Jungaberle, H., Schecke, H., & Klein, M. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.11.008 · Cited by 121
A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens
Barnett, B. S., Siu, W. O., & Pope, H. G. (2018) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000828 · Cited by 116
Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E. S., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., et al. (2024) · Med · doi:10.1016/j.medj.2024.01.005 · Cited by 134
Barrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4981-x · Cited by 109
Self-citationHorizontal gene cluster transfer increased hallucinogenic mushroom diversity
Reynolds, H. T., Vijayakumar, V., Gluck‐Thaler, E., Korotkin, H. B., Matheny, P. B., & Slot, J. C. (2018) · Evolution Letters · doi:10.1002/evl3.42 · Cited by 112
Tryptophan Synthase: Biocatalyst Extraordinaire
Watkins‐Dulaney, E. J., Straathof, S., & Arnold, F. H. (2020) · ChemBioChem · doi:10.1002/cbic.202000379 · Cited by 112
The Enactive Approach to Habits: New Concepts for the Cognitive Science of Bad Habits and Addiction
Ramírez–Vizcaya, S., & Froese, T. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.00301 · Cited by 121
McCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104689 · Cited by 110
Erkizia-Santamaría, I., Alles-Pascual, R., Horrillo, I., Meana, J. J., & Ortega, J. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113612 · Cited by 114
Zeifman, R. J., Wagner, A. C., Watts, R., Kettner, H., Mertens, L. J., & Carhart-Harris, R. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00782 · Cited by 106
“Recent research has indicated that the intensity of “mystical-type” (4, 6, 7, 9, 22) or “peak” experiences engendered by psychedelics (23) is predictive of positive therapeutic outcomes; however, it remains unclear how (i.”
BackgroundKangaslampi, S. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00243 · Cited by 111
Behavioral Neurobiology of Psychedelic Drugs
(2018) · Current topics in behavioral neurosciences · doi:10.1007/978-3-662-55880-5 · Cited by 103
McCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841648 · Cited by 119
Psychedelic therapy in the treatment of addiction: the past, present and future
Zafar, R. R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M. B., Nutt, D., & Erritzøe, D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1183740 · Cited by 113
Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991822 · Cited by 96
Self-citationVan Court, R. C., Wiseman, M. S., Meyer, K. W., Ballhorn, D. J., Amses, K. R., Slot, J. C., Dentinger, B. T. M., Garibay-Orijel, R., & Uehling, J. K. (2022) · Fungal Biology · doi:10.1016/j.funbio.2022.01.003 · Cited by 94
Chi, T., & Gold, J. A. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116715 · Cited by 95
Set and setting: a randomized study of different musical genres in supporting psychedelic therapy
Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00187 · Cited by 97
Hendricks, P. S., Crawford, M. S., Cropsey, K. L., Copes, H., Sweat, N. W., Walsh, Z., & Pavela, G. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117735685 · Cited by 101
Dose–response relationships of psilocybin-induced subjective experiences in humans
Hirschfeld, T., & Schmidt, T. T. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121992676 · Cited by 97
Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy
Horton, D. M., Morrison, B., & Schmidt, J. A. (2021) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.20200055 · Cited by 93
Nayak, S. M., Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., Zaki, H., Brasher, T. J., Lowe, M. X., Jolly, D. R. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1199642 · Cited by 97
Self-citationBeyond the 5-HT2AReceptor: Classic and Nonclassic Targets in Psychedelic Drug Action
Cameron, L. P., Benetatos, J., Lewis, V., Bonniwell, E. M., Jaster, A. M., Moliner, R., Ċastrén, E., McCorvy, J. D., Palner, M., & Aguilar‐Valles, A. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1384-23.2023 · Cited by 100
Psychedelics and health behaviour change
Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzøe, D., Douglass, H. M., Kettner, H., & Carhart-Harris, R. L. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211008554 · Cited by 109
Self-citationBender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
Kiraga, M. K., Mason, N. L., Uthaug, M. V., van Oorsouw, K. I. M., Toennes, S. W., Ramaekers, J. G., & Kuypers, K. P. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.721537 · Cited by 85
McCulloch, D. E.-W., Madsen, M. K., Stenbæk, D. S., Kristiansen, S., Ozenne, B., Jensen, P. S., Knudsen, G. M., & Fisher, P. M. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026454 · Cited by 83
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
Payne, J. E., Chambers, R., & Liknaitzky, P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00034 · Cited by 78
Lea, T., Amada, N. M., Jungaberle, H., Schecke, H., Scherbaum, N., & Klein, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05477-0 · Cited by 76
The therapeutic potential of psilocybin: a systematic review
van Amsterdam, J., & van den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047929 · Cited by 74
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
Spriggs, M. J., Douglass, H. M., Park, R. J., Read, T., Danby, J. L., de Magalhães, F. J. C., Alderton, K. L., Williams, T. M., Blemings, A., Lafrance, A., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.735523 · Cited by 75
Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300501 · Cited by 82
Romeo, B., Hermand, M., Pétillion, A., Karila, L., & Benyamina, A. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.002 · Cited by 76
Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
Divito, A. J., & Leger, R. F. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-06009-x · Cited by 78
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 70
Giluk (2009) · doi:10.1017/s003329172000389x · Cited by 68
Transformative experience and informed consent to psychedelic-assisted psychotherapy
Jacobs, E. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1108333 · Cited by 75
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry
Barber, G., & Dike, C. C. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220525 · Cited by 73
Mertens, L. J., & Preller, K. H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1341-1907 · Cited by 65
Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences
Ballentine, G., Friedman, S. F., & Bzdok, D. (2022) · Science Advances · doi:10.1126/sciadv.abl6989 · Cited by 62
A unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 71
Gandy, S., Forstmann, M., Carhart-Harris, R. L., Timmermann, C., Luke, D. P., & Watts, R. (2020) · Health Psychology Open · doi:10.1177/2055102920978123 · Cited by 70
Use of psilocybin (“mushrooms”) among US adults: 2015–2018
Yockey, R. A., & King, K. A. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00159 · Cited by 64
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
Zeifman, R. J., Singhal, N., Breslow, L., & Weissman, C. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00024 · Cited by 66
Metadata
- Authors
- Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Corresponding author
- Johnson, Matthew W.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2016-07-21
- Volume
- 43
- Issue
- 1
- Pages
- 55-60
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- PMC
- PMC5641975
- OpenAlex
- W2506717582
- Cited by
- 696
- References
- 23
- Citations by year
- 2026: 53 · 2025: 100 · 2024: 89 · 2023: 112 · 2022: 131 · 2021: 63 · 2020: 83 · 2019: 17 · 2018: 31 · 2017: 13 · 2016: 3
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-01-20)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Drug and Alcohol Abuse (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA003889)
- Beckley Foundation (N/A)
- Heffter Research Institute (N/A)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- psilocybin, smoking cessation, smoking abstinence, long-term follow-up, cognitive behavioral therapy, classic psychedelics, addiction treatment, spiritual experience
- MeSH terms
- Combined Modality Therapy, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Pilot Projects, Psilocybin, Cognitive Behavioral Therapy, Smoking Cessation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
